Conflict of interest among Italian medical oncologists: a national survey
暂无分享,去创建一个
F. Roila | L. Fioretto | E. Ballatori | A. Decensi | F. Artioli | G. Numico | M. Tomirotti | M. Clerico | B. Ruggeri | C. Verusio | V. Livellara | Virginia Livellara
[1] A. Blum,et al. What Does ‘Unpaid Consultant’ Signify? A Survey of Euphemistic Language in Conflict of Interest Declarations , 2018, Journal of General Internal Medicine.
[2] Vinay Prasad,et al. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval , 2017, JAMA internal medicine.
[3] Deborah Cohen,et al. Cancer drugs: high price, uncertain value , 2017, British Medical Journal.
[4] H. Naci,et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 , 2017, British Medical Journal.
[5] S. Chimonas,et al. Bringing Transparency to Medicine: Exploring Physicians' Views and Experiences of the Sunshine Act , 2017, The American journal of bioethics : AJOB.
[6] James D. Murphy,et al. Types and Distribution of Payments From Industry to Physicians in 2015 , 2017, JAMA.
[7] W. Stead. The Complex and Multifaceted Aspects of Conflicts of Interest. , 2017, Journal of the American Medical Association (JAMA).
[8] J. Fricker. New NICE criteria for drug access. , 2017, The Lancet Oncology.
[9] J. Wise. Still too little transparency among guideline writers and others , 2017, British medical journal.
[10] W. J. Boscardin,et al. Financial ties of principal investigators and randomized controlled trial outcomes: cross sectional study , 2017, British Medical Journal.
[11] T. Mackey,et al. Distribution and Patterns of Industry-Related Payments to Oncologists in 2014. , 2016, Journal of the National Cancer Institute.
[12] C. Gridelli,et al. The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] Aaron P. Mitchell,et al. Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors. , 2016, JAMA oncology.
[14] E. Klein,et al. Physician compensation for industry-sponsored clinical trials in multiple sclerosis influences patient trust. , 2016, Multiple sclerosis and related disorders.
[15] F. Gilardi,et al. Conflict of interest between professional medical societies and industry: a cross-sectional study of Italian medical societies’ websites , 2016, BMJ Open.
[16] M. McCarthy. PubMed is urged to include competing interest information in abstracts , 2016, British medical journal.
[17] Suzanne M. Miller,et al. Financial Concerns About Participation in Clinical Trials Among Patients With Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Sonya Cressman,et al. A Time-Trend Economic Analysis of Cancer Drug Trials. , 2015, The oncologist.
[19] Vinay Prasad,et al. Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs. , 2015, JAMA oncology.
[20] J. Lenzer,et al. Diverting attention from financial conflicts of interest , 2015, British medical journal.
[21] P. Gøtzsche,et al. Under-reporting of conflicts of interest among trialists: a cross-sectional study , 2015, Journal of the Royal Society of Medicine.
[22] M. McCarthy. US doctors earn speaking and consulting fees from drug companies that sponsor their research , 2014, British medical journal.
[23] L. Wen. Patients can’t trust doctors’ advice if we hide our financial connections with drug companies , 2014, BMJ : British Medical Journal.
[24] T. Fojo,et al. Cancer drugs in the United States: Justum Pretium--the just price. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] C. Weijer,et al. What do Canadians think about physician-pharmaceutical industry interactions? , 2013, Health policy.
[26] D. Pfister. The just price of cancer drugs and the growing cost of cancer care: oncologists need to be part of the solution. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] B. Egleston,et al. Correlation between financial relationships with commercial interests and research prominence at an oncology meeting. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Edward S. Kim,et al. Physician and stakeholder perceptions of conflict of interest policies in oncology. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Laurance. Makers of anticancer drugs are “profiteering,” say 100 specialists from around the world , 2013, British medical journal.
[30] A. Abernethy,et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. , 2013, The Oncologist.
[31] A. Flanagin,et al. Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey , 2011, BMJ : British Medical Journal.
[32] Natasha Das,et al. Plagiarism: Why is it such a big issue for medical writers? , 2011, Perspectives in clinical research.
[33] Andreas Lundh,et al. Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue – Cohort Study , 2010, PLoS medicine.
[34] S. Joffe,et al. Relationships between authorship contributions and authors' industry financial ties among oncology clinical trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] D. Grande. A national survey of physician-industry relationships. , 2007, The New England journal of medicine.
[36] E. Emanuel,et al. Patients' views on financial conflicts of interest in cancer research trials. , 2006, The New England journal of medicine.
[37] L. Saltz. Perspectives on Cost and Value in Cancer Care. , 2016, JAMA oncology.
[38] Sergio Sismondo,et al. Industry sponsorship and research outcome. , 2012, The Cochrane database of systematic reviews.